Valore202020212022202320242025TTMSpese di vendita, generali e amministrative9.8 M10.86 M10.32 M9.73 M9.44 M8.89 M—Ricerca e sviluppo22.76 M28.69 M30.65 M34.47 M24.81 M22.76 M—Reddito operativo-31.5 M-35.07 M-35.37 M-12.99 M-14.89 M31.33 M—Proventi non operativi, Totale1.83 M893 K1.78 M3.25 M5.22 M4.1 M—Oneri finanziari, al netto degli interessi capitalizzati———————Proventi non operativi, esclusi gli oneri finanziari1.83 M893 K1.78 M3.25 M5.22 M4.1 M—Entrate/uscite straordinarie———————Utile al lordo delle imposte-29.7 M-34.2 M-33.64 M-9.78 M-9.71 M35.4 M-17.73 MQuota di utile———————Imposte0058 K8.97 M4.52 M54 K—Interessi di minoranza———————Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MAttività cessate———————Utile netto-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MUtile base per azione (EPS base)-0.37-0.41-0.39-0.21-0.160.38—Utile diluito per azione (EPS diluito)-0.37-0.41-0.39-0.21-0.160.38-0.23Numero medio di azioni ordinarie in circolazione79.59 M84.2 M86.56 M87.63 M89.53 M93.43 M357.14 MAzioni diluite in circolazione79.59 M84.2 M86.56 M87.63 M89.53 M93.82 M357.53 MEBITDA-29.95 M-33.32 M-28.87 M-12.19 M-14.4 M31.8 M—EBIT-31.5 M-35.07 M-35.37 M-12.99 M-14.89 M31.33 M—Costo del fatturato60 K680 K975 K2 M7.93 M9.25 M—Altri costi del venduto———————Ammortamento e svalutazione (liquidità)1.54 M1.75 M6.5 M801 K486 K475 K—
Compugen Ltd
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.